Schwab Charles Investment Management Inc. lifted its position in shares of Theravance Biopharma, Inc. (NASDAQ:TBPH) by 9.0% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 177,317 shares of the biopharmaceutical company’s stock after purchasing an additional 14,709 shares during the period. Schwab Charles Investment Management Inc. owned 0.33% of Theravance Biopharma worth $7,065,000 at the end of the most recent quarter.

Several other institutional investors have also recently added to or reduced their stakes in the company. Russell Investments Group Ltd. increased its stake in shares of Theravance Biopharma by 46.1% during the 2nd quarter. Russell Investments Group Ltd. now owns 21,465 shares of the biopharmaceutical company’s stock worth $855,000 after purchasing an additional 6,777 shares during the last quarter. Aperio Group LLC acquired a new position in Theravance Biopharma in the 2nd quarter valued at about $205,000. Goldman Sachs Group Inc. grew its stake in Theravance Biopharma by 341.2% in the 1st quarter. Goldman Sachs Group Inc. now owns 256,110 shares of the biopharmaceutical company’s stock valued at $9,430,000 after buying an additional 198,062 shares during the last quarter. Driehaus Capital Management LLC acquired a new position in Theravance Biopharma in the 1st quarter valued at about $1,235,000. Finally, Paloma Partners Management Co grew its stake in Theravance Biopharma by 52.5% in the 1st quarter. Paloma Partners Management Co now owns 20,558 shares of the biopharmaceutical company’s stock valued at $757,000 after buying an additional 7,080 shares during the last quarter. Institutional investors own 84.84% of the company’s stock.

TRADEMARK VIOLATION NOTICE: “Theravance Biopharma, Inc. (TBPH) Stake Lifted by Schwab Charles Investment Management Inc.” was originally reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this report on another website, it was copied illegally and republished in violation of international trademark and copyright laws. The legal version of this report can be read at https://www.thecerbatgem.com/2017/10/09/theravance-biopharma-inc-tbph-stake-lifted-by-schwab-charles-investment-management-inc.html.

In related news, SVP Frank Pasqualone acquired 4,000 shares of the stock in a transaction on Monday, August 21st. The shares were acquired at an average price of $26.34 per share, with a total value of $105,360.00. Following the completion of the transaction, the senior vice president now owns 213,180 shares in the company, valued at approximately $5,615,161.20. The purchase was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Henrietta Fore bought 6,000 shares of Theravance Biopharma stock in a transaction dated Friday, August 11th. The stock was acquired at an average price of $23.99 per share, with a total value of $143,940.00. Following the purchase, the director now directly owns 24,000 shares of the company’s stock, valued at $575,760. The disclosure for this purchase can be found here. In the last ninety days, insiders acquired 20,000 shares of company stock worth $494,300. Insiders own 6.10% of the company’s stock.

Theravance Biopharma, Inc. (TBPH) opened at 35.66 on Monday. Theravance Biopharma, Inc. has a 52 week low of $23.15 and a 52 week high of $43.44. The company has a 50-day moving average of $31.91 and a 200-day moving average of $35.51. The firm’s market cap is $1.92 billion.

TBPH has been the topic of a number of research reports. Cantor Fitzgerald initiated coverage on shares of Theravance Biopharma in a research note on Friday, June 16th. They issued an “overweight” rating and a $55.00 price target on the stock. BidaskClub upgraded shares of Theravance Biopharma from a “hold” rating to a “buy” rating in a research note on Saturday, June 24th. ValuEngine lowered shares of Theravance Biopharma from a “hold” rating to a “sell” rating in a research note on Tuesday, August 1st. Needham & Company LLC reiterated a “buy” rating on shares of Theravance Biopharma in a research note on Wednesday, August 2nd. Finally, Evercore ISI initiated coverage on shares of Theravance Biopharma in a research note on Wednesday, August 16th. They issued an “outperform” rating and a $45.00 price target on the stock. Four investment analysts have rated the stock with a sell rating, one has given a hold rating and five have assigned a buy rating to the company. The company presently has an average rating of “Hold” and an average target price of $43.00.

About Theravance Biopharma

Theravance Biopharma, Inc is a biopharmaceutical company. The Company is engaged in creating medicines for patients suffering from serious illness. The Company operates in the segment of discovery (research), development and commercialization of human therapeutics. The Company’s pipeline of internally discovered product candidates includes medicines to address the unmet needs of patients being treated for serious conditions primarily in the acute care setting.

Want to see what other hedge funds are holding TBPH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Theravance Biopharma, Inc. (NASDAQ:TBPH).

Institutional Ownership by Quarter for Theravance Biopharma (NASDAQ:TBPH)

Receive News & Stock Ratings for Theravance Biopharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theravance Biopharma Inc. and related stocks with our FREE daily email newsletter.